5月26日 - ** 药物开发商Outlook Therapeutics（OTLK.O）的股价在盘前交易中上涨58%，至49美分
** 该公司表示，计划于6月重新提交其眼部疾病治疗药物的上市申请，此前美国食品药品监督管理局（FDA）于去年12月拒绝批准该申请
** OTLK的治疗药物Lytenava针对湿性年龄相关性黄斑变性，这是一种常见的眼部疾病，因视网膜血管渗漏导致视力丧失
** OTLK表示，FDA在对Outlook上诉的正式回复中认定，Lytenava已确立了充分的有效性证据
** Lytenava是FDA批准药物贝伐珠单抗的一种特定、经官方授权的制剂
** 截至上一交易日收盘，该股年内累计跌幅达80%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.